Tuesday, October 11, 2011

Study: Gates project spared 100K Indians from HIV (AP)

An estimated 100,000 people in India may have escaped HIV infection over five years thanks to one of the world's biggest prevention programs, an encouraging sign that targeting high-risk groups remains vital even as more donors focus on treatment, a new study suggests.

While the initial findings regarding the $258 million Avahan project, funded by the Bill & Melinda Gates Foundation, come with large uncertainty due to data limitations and methodology, the study's authors say the overall message is clear: that investing in prevention can make a dent in one of the world's largest epidemics, with an estimated 2.4 million Indians infected.

The program was assessed from 2003 to 2008 in six Indian states, home to 300 million people and the country's highest HIV rates when it started. It involved needle exchanges, safe-sex counseling, condom distribution and other interventions to reach vulnerable groups, including truck drivers, injecting drug users, men who have sex with other men, and prostitutes, along with their clients and partners. The project's aim was to reduce the number of infections infiltrating the general population by targeting those who posed the highest risk.

The assessment published Tuesday in The Lancet medical journal suggests that higher Avahan grants per infected person correlated with fewer HIV cases in the general population in the southern states of Andhra Pradesh, Karnataka and Maharashtra. However, that was not the case in southern Tamil Nadu and the small northeastern states of Manipur and Nagaland.

Part of the difference may be linked to the epidemics, with sex the main mode of transmission in the crowded south and injecting drug use the top driver in the remote northeast, said co-author Dr. Lalit Dandona, a professor at the Public Health Foundation of India. In Tamil Nadu, the authors, who are also from the University of Washington, note that HIV levels were already lower there because other prevention programs were already running when Avahan began.

In Karnataka, the program was linked to a 13 percent drop in overall HIV rates, the largest observed. Maharashtra saw the smallest decline, just over 2 percent.

In all six states, an estimated 100,178 HIV infections were averted due to the program, which is the best possible outcome with the available data, Dandona said.

The study, also funded by the Gates Foundation, explains that the conclusions do come with a degree of uncertainty, mainly because pregnant women from antenatal clinics were used as the data source even though corrections for this were factored into the calculations.

Dr. Prabhat Jha, director of the Centre for Global Health Research in Canada, who has conducted large-scale HIV studies in India, said those data are typically used to monitor trends or changes in the epidemic, not to estimate infections averted in the general population.

"Right from the start, it just doesn't work," he said. "I'm not going to judge how high my plane is flying by how many times my ears pop. It doesn't tell you where you're at."

Jha also noted that other prevention programs were in place before Avahan began and that HIV infections were already in decline. Instead of focusing on infections averted, he said it makes more sense to assess the program more broadly.

"There is substantial evidence that most new HIV infections in India arise from sex work, so taking sex work seriously means it will generate benefits," he said. "Even if these are hard to quantify."

Avahan, which translates from Sanskrit as "call to action," has been criticized by some for throwing large sums of money at the problem and creating more waste than results. As the Gates Foundation's largest HIV prevention program in a single country, the organization donated an additional $80 million to the project in 2009. The Indian government is expected to take it over.

In an accompanying commentary, World Health Organization experts Ties Boerma and Isabelle de Zoysa said that despite many remaining questions about the project's overall success, the findings are an encouraging first step. "However, seven years into the project, many questions remain unanswered," they wrote.



Powered By WizardRSS.com | Full Text RSS Feed | Amazon Plugin | Settlement Statement

Monday, October 10, 2011

Paralyzed man uses mind-powered robot arm to touch (AP)

PITTSBURGH � Giving a high-five. Rubbing his girlfriend's hand. Such ordinary acts � but a milestone for a paralyzed man.

True, a robotic arm parked next to his wheelchair did the touching, painstakingly, palm to palm. But Tim Hemmes made that arm move just by thinking about it.

Emotions surged. For the first time in the seven years since a motorcycle accident left him a quadriplegic, Hemmes was reaching out to someone � even if it was only temporary, part of a monthlong science experiment at the University of Pittsburgh.

"It wasn't my arm but it was my brain, my thoughts. I was moving something," Hemmes says. "I don't have one single word to give you what I felt at that moment. That word doesn't exist."

The Pennsylvania man is among the pioneers in an ambitious quest for thought-controlled prosthetics to give the paralyzed more independence � the ability to feed themselves, turn a doorknob, hug a loved one.

The goal is a Star Trek-like melding of mind and machine, combining what's considered the most humanlike bionic arm to date � even the fingers bend like real ones � with tiny chips implanted in the brain. Those electrodes tap into electrical signals from brain cells that command movement. Bypassing a broken spinal cord, they relay those signals to the robotic third arm.

This research is years away from commercial use, but numerous teams are investigating different methods.

At Pittsburgh, monkeys learned to feed themselves marshmallows by thinking a robot arm into motion. At Duke University, monkeys used their thoughts to move virtual arms on a computer and got feedback that let them distinguish the texture of what they "touched."

Through a project known as BrainGate and other research, a few paralyzed people outfitted with brain electrodes have used their minds to work computers, even make simple movements with prosthetic arms.

But can these neuroprosthetics ever offer the complex, rapid movements that people would need for more practical, everyday use?

"We really are at a tipping point now with this technology," says Michael McLoughlin of the Johns Hopkins University Applied Physics Laboratory, which developed the humanlike arm in a $100 million project for DARPA, the Pentagon's research agency.

Pittsburgh is helping to lead a closely watched series of government-funded studies over the next two years to try to find out. A handful of quadriplegic volunteers will train their brains to operate the DARPA arm in increasingly sophisticated ways, even using sensors implanted in its fingertips to try to feel what they touch, while scientists explore which electrodes work best.

"Imagine all the joints that are in your hand. There's 20 motions around all those joints," says Pittsburgh neurobiologist Andrew Schwartz. "It's not just reaching out and crudely grasping something. We want them to be able to use the fingers we've worked so hard on."

The 30-year-old Hemmes' task was a much simpler first step. He was testing whether a new type of chip, which for safety reasons the Food and Drug Administration let stay on this initial volunteer's brain for just a month, could allow for three-dimensional arm movement.

He surprised researchers the day before the electrodes were removed. The robotic arm whirred as Hemmes' mind pushed it forward to hesitantly tap palms with a scientist. Then his girlfriend beckoned. The room abruptly hushed. Hemmes painstakingly raised the black metal hand again and slowly rubbed its palm against hers a few times.

These emotional robotic touches have inspired researchers now recruiting volunteers for soon-to-start yearlong experiments.

"It was awesome," is the decidedly unscientific description from the normally reserved Dr. Michael Boninger, rehabilitation chief at the University of Pittsburgh Medical Center. "To interact with a human that way. ... This is the beginning."

___

Hemmes' journey began in 2004. He owned an auto-detailing shop and rode his motorcycle in his spare time. Then one summer evening he swerved to miss a deer. His bike struck a guardrail. His neck snapped.

His determination didn't. Paralyzed below the shoulders, he's tried other experimental procedures in hopes, so far unrealized, of regaining some arm function.

"I always tell people your legs are great ... but they just get you from here to there," Hemmes says as his caregiver waits to feed him a bite of a cheeseburger near his home in Butler, north of Pittsburgh. "Your arms and fingers and hands do everything else. I have to get those back, I absolutely have to."

His ultimate goal is to hug his 8-year-old daughter. "I'm going to do whatever it takes, as long as it takes, to do that again."

Hemmes entered an operating room at UPMC with a mix of nerves and excitement.

"It's good anxiety," he says. "There is so much riding on this."

___

Think "I want that apple," and your arm reaches out and grasps it. You're not aware that neurons are instantaneously firing in patterns that send commands down the spinal cord � make the shoulder raise the arm, extend the elbow, flex the wrist and all five fingers.

A very similar firing occurs when you imagine movement or watch the movement you'd like to perform, explains Boninger, who with Schwartz is leading the Pittsburgh research together with a team of bioengineers, neuroscientists and physicians.

The DARPA arm was developed primarily for amputees. Separate research is under way to help them move it by using transplanted nerves to sense those brain commands. The paralyzed pose a more difficult challenge: getting those signals around a broken spinal cord.

For quadriplegic patients, scientists use implanted electrodes, called a "brain-computer interface" or BCI, to record that electrical activity. The signals move down through wires that tunnel under the skin and out by the collarbone, and are plugged into a computer or a robotic arm.

Until now, researchers mostly have tested miniature electrodes that poke inside the brain's motor cortex and record from individual cells, presumably allowing for precise movements. Pittsburgh's next test-patient will have two penetrating grids implanted in different parts of the cortex for a year to record from 200 cells altogether.

In contrast, Hemmes' chip sat on the surface of his motor cortex, a less invasive method that records from groups of cells. The size of two postage stamps, it's based on a kind of electrical signal mapping used to track seizures in epilepsy patients.

Both approaches need study, says Daofen Chen of the National Institutes of Health, who oversees neurorehabilitation research. He compares the options to eavesdropping on a party by sending in individual microphones or setting up a recorder at the window.

Boninger adds that scar tissue can blunt the penetrating electrodes over time, and the surface chips may be easier to convert to a wireless system, which is important for commercial use.

___

Hemmes' operation took two hours. He had practiced imagining arm movements inside brain scanners, to see where the electrical signals concentrated. That's where neurosurgeon Elizabeth Tyler-Kabara cut, attaching the chip through an inch-wide opening on the left side of Hemmes' skull.

Two days later, Hemmes was hooked to a computer, beginning simple cursor movements. The next week, it was time to test if he could trigger real-life movement using the DARPA arm.

Hemmes reclined in his wheelchair, the robot arm bolted to a steel rod nearby. The task: make the arm reach out to grasp a ball mounted on a board.

The arm whirs forward, then stops, then goes again, then suddenly pulls back.

"It's doing the opposite of what I ask it do," Hemmes says in frustration. "When I think about reaching back, it goes forward."

Dr. Wei Wang, a member of the research team, watches Hemmes' brain patterns on a nearby computer screen, trying to match them to the robotic movements. Focus on your elbow, Wang advises.

Hemmes takes a deep breath and tries. The arm whirs forward this time, reaching the ball. The fingers clench around it.

"There's no owner's manual," Hemmes says, thrilled that the back-and-forth pays off. "I'm training my brain to figure how to do all this."

Letting go is harder, the motor growling as the arm tugs backward before the fingers fully release. Hemmes starts imagining his hand relaxing before pulling backward, and the robot hand follows.

___

Sure, a robotic hand that one day mounts to a wheelchair could be useful. But no matter how well today's prosthetics move, they've got a problem: They don't sense what they touch. Normally, instant messages flash from the skin up to the brain to say "squeeze tighter" so we don't drop that coffee cup, or "tight enough" so we don't hug too hard.

Besides, Hemmes shares the dream of many quadriplegics. He doesn't want a bionic third hand. He wants to move his own hands again.

"These are all scientific goals that are very real," Boninger says.

Recreating sensation means crafting a two-way highway with those brain chips. That's what Duke University, in a study published last week in the journal Nature, did with its two monkeys. When the animals "touched" objects on a computer screen with their video game-like arms, electrical signals flashed back up to implanted electrodes � different signals for different textures, to tell the objects apart.

Sensors in the DARPA arm's fingertips allow for that same kind of feedback. McLoughlin says the plan is for one of the Pittsburgh study patients to begin testing touch capability next year, with a similar attempt at the California Institute of Technology to follow.

What about moving paralyzed limbs? Duke's plan is to turn its research into a robotic exoskeleton that would help the paralyzed move their bodies.

Hemmes is more intrigued by what's called functional electrical stimulation, zapping muscles with electrical currents to make them move. At Hemmes' request, Boninger's team attempted to fit his hand with a stimulator glove that might be linked to his electrode, but it was unsuccessful. The NIH's Chen says still other researchers are working on that kind of approach.

___

Hemmes likened moving the DARPA arm to learning to drive a car with a manual transmission. It took practice, but by week four he was moving the arm sideways as well as back and forth.

The fingers still clenched pretty tight, though. So when his girlfriend Katie Schaffer spoke up � "I want to hold your hand," she said on his last day of testing � Hemmes didn't dare bend them.

The two met after his accident, so he'd never before reached out to her.

"I was just trying to be gentle. I didn't want to hurt her, and I finally got there," Hemmes says. "Definitely the tears were flowing."

He says he was ready for a break after almost daily scientific testing, so removing the electrode and wires the next day wasn't a disappointment. He's confident the researchers will call him back once the technology advances.

"I believe this is the future," he says. "Just let people know there's hope."



Powered By WizardRSS.com | Full Text RSS Feed | Amazon Plugin | Settlement Statement

Saturday, October 8, 2011

Listeria outbreak draws Seattle lawyer to battle (AP)

SEATTLE � Bill Marler updates his many blogs each day about the latest foodborne illness outbreak and travels the world delivering speeches, imploring the food industry to improve its safety measures. All this while working the phones to get money for the victims.

Like it or not, the personal injury attorney behind most every lawsuit associated with foodborne outbreaks is also known away from the courtroom as one of the nation's leading food safety advocates. He's always raising red flags about what he considers lax industry testing or inadequate government oversight.

Marler created a niche for himself since winning his first settlement in 1993 � $15.6 million for a girl sickened by E. coli from a Jack in the Box hamburger. He's in the forefront again thanks to a listeria outbreak in cantaloupe that has sickened more than 100 people and killed at least 21.

His firm already has filed six lawsuits against Colorado grower Jensen Farms, where federal health authorities say the listeria outbreak originated, and a distributor. While Jensen recalled more than 300,000 cases of cantaloupe, neither the U.S. Centers for Disease Control and Prevention nor the Food and Drug Administration have determined the source of the outbreak.

Critics contend his advocacy work isn't based on the best available science and mainly serves to benefit his law firm. Colleagues call him a dedicated attorney who advocates for his clients and knows the subject matter as well or better than anyone else.

"A lot of people who don't know me very well see the workaholic, always traveling, the persona, but what I've tried to do with my job is to make it more of a vocation," he said. "I love what I do, and I believe in what I do."

His clients lavish praise on him.

Linda Rivera, 59, was hospitalized for two years after getting ill from E. coli in cookie dough. Her husband, Richard, said he had a list of three attorneys to call, and when the first two heard Marler was also on the list, they deferred.

"These people gave up cases, money, because they knew he was the best," he said. "It wasn't about money. Bill gave me peace of mind to know I can take care of Linda. He's definitely leaving a legacy and having an impact on food safety."

In his downtown Seattle offices overlooking Puget Sound, employees wear jeans to work and on this day Marler is casual in khakis and tennis shoes. The walls are lined with framed newspaper clippings and magazine articles depicting his victories, along with framed copies of checks from those cases.

Marler says his firm has won settlements totaling more than $600 million from some of the food industry's biggest players: Cargill, Wal-Mart, Dole.

But it hasn't all been smooth sailing.

Miffed about being denied a partnership just short of four years into his tenure at a Seattle firm and feeling unappreciated in the midst of the Jack in the Box case, Marler packed up his office on a Sunday evening and left a resignation letter on the founding partner's chair. His coworkers' were stunned on Monday to find his office empty.

Now 54, he says he's gotten smarter, though no less preoccupied with work. He donated the money for the bar bill at his last high school reunion, then forgot to attend. He said he makes a concerted effort to carve out time for his wife and three teenage daughters.

Rosemary Mucklow, director emeritus of the National Meat Association, said plenty of people in the meat industry don't like his lawsuit "happy" ways, but that Marler is always willing to try to find common ground. Several years ago, an apoplectic member called her to get Marler's publicity machine toned down, and Marler agreed to remove a photo from his web site.

"Happy to comply," Mucklow recalled Marler saying. "I've always remembered what he said. That's the difference with him and a lot of the lawyers I've done business with."

Alan Maxwell, an Atlanta-based attorney who has defended companies against Marler in a number of foodborne illness cases, said his clients don't always agree with Marler's public relations outreach, but most generally respect him and find him to be fair.

"The fact is Bill knows the subject matter as well as or better than any lawyer, not to mention many scientists in food safety," Maxwell said.

Two years ago, Marler petitioned the federal government to ban strains of E. coli that can cause illnesses equally as serious as the most virulent strain, O157:H7. As a result of those efforts, the U.S. Department of Agriculture recently announced plans to begin testing for the strains in beef trimmings, beginning next year, despite industry opposition.

He considers it one of his greatest professional successes, along with a decision by Odwalla, another defendant, to begin pasteurizing its juices following a 1996 E. coli outbreak.

But regulators shouldn't be applying a blanket ban to E. coli strains, argues Michael Doyle, director of the University of Georgia's Center for Food Safety. Rather, they should be focusing on strains that produce toxin resulting in severe illness.

"As a scientist, I would hope that his approach would be science based, because science is a critical part of public health," he said. "I think there could have been better science used in developing the new rule."

However, Doyle also said that Marler the lawyer is using the law to enhance food safety, and that's a good thing.

Marler's positions might not always be scientifically supported, said Dave Theno of Gray Dog Partners Inc., a consulting firm to the food industry, but because he's representing the consumer's best interests, it's up to industry to find a way to improve things.

Theno was the chief food safety officer for Jack in the Box Inc. and sat across the table from Marler in the 1990s E. coli cases. Today, Theno considers Marler a friend, colleague and co-advocate for food safety who has seen firsthand the suffering of victims.

"Unfortunately, these things don't happen overnight," he said. "But Bill and I have both been there, and when you're there, the world is never the same. This is a mission. It's not a job."



Powered By WizardRSS.com | Full Text RSS Feed | Amazon Plugin | Settlement Statement

Friday, October 7, 2011

New prostate cancer test advice overturns dogma (AP)

WASHINGTON � Men finally may be getting a clearer message about undergoing PSA screening for prostate cancer: Don't do it.

They may not listen. After all, the vast majority of men over 50 already get tested.

The idea that finding cancer early can harm instead of help is a hard one to understand. But it's at the heart of a government panel's draft recommendation that those PSA blood tests should no longer be part of routine screening for healthy men.

The U.S. Preventive Services Task Force examined all the evidence and found little if any reduction in deaths from routine PSA screening. But it did conclude that too many men are diagnosed with tumors that never would have killed them and suffer serious side effects from resulting treatment.

That recommendation isn't final � it's a draft open for public comment. But it goes a step further than several major cancer groups including the American Cancer Society, which urges that men be told the pros and cons and decide for themselves.

The new advice is sure to be hugely controversial. Already some doctors are rejecting it.

"We all agree that we've got to do a better job of figuring out who would benefit from PSA screening. But a blanket statement of just doing away with it altogether ... seems over-aggressive and irresponsible," said Dr. Scott Eggener, a prostate cancer specialist at the University of Chicago.

In the exam room, explaining the flaws in PSA testing has long been difficult.

"Men have been confused about this for a very long time, not just men patients but men doctors," said Dr. Yul Ejnes, a Cranston, R.I., internal medicine specialist who chairs the American College of Physicians' board of regents.

He turned down his own physician's offer of a PSA test after personally reviewing the research.

"There's this dogma ... that early detection saves lives. It's not necessarily true for all cancers," Ejnes said.

That's an emotional shift, as the American Cancer Society's Dr. Len Lichtenfeld voiced on his blog on Friday.

"We have invested over 20 years of belief that PSA testing works. ... And here we are all of these years later, and we don't know for sure," Lichtenfeld wrote. "We have been poked and probed, we have been operated on by doctors and robots, we have been radiated with fancy machines, we have spent literally billions of dollars. And what do we have? A mess of false hope?"

Too much PSA, or prostate-specific antigen, in the blood only sometimes signals prostate cancer is brewing. It also can mean a benign enlarged prostate or an infection. In fact, most men who undergo a biopsy for an abnormal PSA test don't turn out to have prostate cancer.

Screening often detects small tumors that will prove too slow-growing to be deadly � by one estimate, in 2 of every 5 men whose cancer is caught through a PSA test. But there's no way to tell in advance who needs treatment.

"If we had a test that could distinguish between a cancer that was going to be aggressive and a cancer that was not, that would be fabulous," said Dr. Virginia Moyer of the Baylor College of Medicine, who chairs the task force, an independent expert group that reviews medical evidence for the government.

About 1 in 6 U.S. men will be diagnosed with prostate cancer at some point in their life. Yet the cancer society notes that in Western European countries where screening isn't common, 1 in 10 men are diagnosed and the risk of death in both places is the same. In the U.S., about 217,000 men are diagnosed with prostate cancer each year, and 32,000 die.

Why not screen in case there's a mortality benefit that studies have yet to tease out? The task force outlined the problem with that:

_Up to 5 in every 1,000 men die within a month of prostate cancer surgery, and between 10 and 70 more suffer serious complications.

_At least 200 to 300 of every 1,000 men treated with surgery or radiation suffer incontinence or impotence.

_Overall, Moyer said 30 percent of men who are treated for PSA-discovered prostate cancer suffer significant side effects from the resulting treatment.

Among the questions sure to be raised during the public comment period are how doctors should advise men with prostate cancer in the family or black men, who are at increased risk.

PSA testing also is used to examine men with prostate symptoms, and to check men who already have had prostate cancer. The new recommendation doesn't affect those uses.

Congress requires that Medicare cover PSA tests, at a cost of $41 million in 2009. Other insurers follow Medicare's lead, especially in light of conflicting recommendations.

Nor does the new recommendation mean that men who want a PSA test can't have one. If the rule is adopted � something the government will review once the task force hears comments and finalizes its guidance � it would just advise against doctors pushing it routinely.

"The truth is that like so many things in medicine, there's no one-size-fits-all," said Dr. Michael Barry of Massachusetts General Hospital who heads the Foundation for Informed Medical Decision-Making that backs ways to help patients make their own choices.

___

AP Medical Writer Lindsey Tanner in Chicago contributed to this report.

___

Online:

PSA decision guide: http://bit.ly/cXq1QE



Powered By WizardRSS.com | Full Text RSS Feed | Amazon Plugin | Settlement Statement

Chemical makers say BPA no longer used in bottles (AP)

WASHINGTON � Makers of the controversial chemical bisphenol-A have asked federal regulators to phase out rules that allow its use in baby bottles and sippy cups, saying those products haven't contained the plastic-hardening ingredient for two years.

The unusual request from the American Chemistry Council may help quash years of negative publicity from consumer groups and head off tougher laws that would ban the chemical from other types of packaging because of health worries.

For now, the industry says concerns over bottles and spill-proof cups are unnecessary.

"All the evidence we have is that those products have been off the market for several years," said Steven Hentges, the American Chemistry Council's director for BPA issues. "We're trying to bring clarity and certainty that BPA isn't used in baby bottles and sippy cups today, and it won't be in the future."

BPA is found in hundreds of plastic items from water bottles to CDs to dental sealants. Some researchers are convinced that ingesting the chemical can interfere with development of the reproductive and nervous systems and possibly promote cancer.

Consumer health groups hailed the move as a "win for moms and dads" but pressed for removing BPA from more products.

"The writing is on the wall for BPA," said Mike Schade of the Center for Health, Environment and Justice. "We hope to see a major transition away from BPA in canned food in years to come."

The chemical industry's petition points out that the six leading makers of baby bottles stopped using BPA in 2009. And none of the 13 major BPA producers, which make 97 percent of the global supply, sells the chemical to bottle makers.

The group represents BPA producers including Dow Chemical Co., Bayer and Momentive. The companies maintain that BPA is safe and the decision to petition the FDA was not influenced by science.

The FDA regulates chemicals used in food packaging. It is illegal for companies to use substances not covered by FDA rules.

Agency spokesman Douglas Karas said the industry information is "consistent" with its own research, suggesting regulators would approve the request. The FDA typically takes comments on petitions for 60 days before making a decision.

The industry move also appears designed to head off state-level efforts to ban BPA across the U.S. On Wednesday, California became the 11th state to pass a law banning bisphenol from baby drink containers. Connecticut, Maryland, Minnesota, New York and a half-dozen other states have passed similar laws in the past two years.

"This move eliminates the need for state and federal governments to spend further time and effort on a matter that has no practical outcome," the group said in a statement.

Consumers Union, a nonprofit advocacy group, pointed out that "the industry collectively spent millions of dollars over the last five years" lobbying against the BPA state bans.

"The chemical industry's action doesn't go far enough. They need to get on board with a national ban on BPA in all food and beverage containers," said Ami Gadhia, the group's senior counsel.

Legislation introduced by Rep. Ed Markey, D-Mass., and other federal lawmakers would ban BPA nationwide in all canned food, water bottles and food containers. Those products are not addressed in the industry's petition.

The vast majority of canned goods in the U.S. are sealed with resin that contains BPA to prevent contamination and spoiling. Canned food manufacturers have used the chemicals since the 1950s. The practice is approved by the FDA.

But some manufacturers have responded to concerns by switching to alternatives. Heinz uses BPA-free coatings for its Nurture baby formula cans, and ConAgra and General Mills have switched to alternative sealants for some canned tomatoes.

The chemical industry says BPA is the safest, most effective sealant.

The federal government has been grappling with the safety of BPA for nearly three years. The FDA revised its opinion on BPA in 2010 saying there is "some concern" about the chemical's impact on the brain and reproductive system of infants, babies and young children. Previously the agency said the trace amounts of BPA that leach out of food containers are not dangerous.

The FDA said dozens of animal studies linking the chemical to tumors and abnormal growth are not applicable to humans. The government is spending $30 million to study the chemical's effect on people.

About 90 percent of Americans have traces of bisphenol in their urine.

While older children and adults quickly eliminate the chemical through their kidneys, newborns and infants can retain it for much longer. Scientists pushing for a ban on the chemical argue that BPA mimics the effects of the hormone estrogen, interfering with growth.



Powered By WizardRSS.com | Full Text RSS Feed | Amazon Plugin | Settlement Statement

FDA approves first diabetes-cholesterol combo pill (AP)

WASHINGTON � The Food and Drug Administration has approved a Merck drug as the first combination pill for patients with diabetes who also have high cholesterol.

Patients with both diabetes and high cholesterol are at increased risk for heart disease, stroke, kidney disease and other chronic conditions.

The drug Juvisync combines Merck's diabetes pill Januvia with the popular cholesterol drug Zocor.

The American Diabetes Association recommends all people with diabetes over 40 take a cholesterol-lowering drug, known as a statin. But Merck scientists say many as 4 million diabetes patients in the U.S. are not following that recommendation.

About 20 million people in the U.S. have type 2 diabetes, which prevents them from properly breaking down carbohydrates. Patients with the condition are at a higher risk of a number of complications.



Powered By WizardRSS.com | Full Text RSS Feed | Amazon Plugin | Settlement Statement